219 related articles for article (PubMed ID: 27080472)
21. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
Chan SL; Yeo W; Mo F; Chan AWH; Koh J; Li L; Hui EP; Chong CCN; Lai PBS; Mok TSK; Yu SCH
Cancer; 2017 Oct; 123(20):3977-3985. PubMed ID: 28640364
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
24. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):373-382. PubMed ID: 28378918
[TBL] [Abstract][Full Text] [Related]
25. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
[TBL] [Abstract][Full Text] [Related]
27. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
29. Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.
Mizuno R; Mikami S; Takamatsu K; Shinojima T; Kikuchi E; Oya M
Jpn J Clin Oncol; 2017 Dec; 47(12):1170-1174. PubMed ID: 28977627
[TBL] [Abstract][Full Text] [Related]
30. Axitinib controlled metastatic renal cell carcinoma for 5 years.
Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M
Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123
[TBL] [Abstract][Full Text] [Related]
32. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
33. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
Yang LP; McKeage K
Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
35. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
O'Sullivan C; Edgerly M; Velarde M; Wilkerson J; Venkatesan AM; Pittaluga S; Yang SX; Nguyen D; Balasubramaniam S; Fojo T
J Clin Endocrinol Metab; 2014 Apr; 99(4):1291-7. PubMed ID: 24423320
[TBL] [Abstract][Full Text] [Related]
36. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
38. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
39. Individualized dosing with axitinib: rationale and practical guidance.
Schmidinger M; Danesi R; Jones R; McDermott R; Pyle L; Rini B; Négrier S
Future Oncol; 2018 Apr; 14(9):861-875. PubMed ID: 29264944
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]